Company: SXTPW
Filing Date: 2025-09-05
Form Type: 424B5
Source: 0001213900-25-085050
Chunk: 31

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-09-05
Form: 424B5
Chunk 31
---
 Common Stock outstanding immediate after this offering:Up to 5,061,683 shares of our common stock, assuming sales of 957,214 shares of our common stock in this offering at a public offering price of $1.46 per share, which was the last reported sale price per share of our common stock on The Nasdaq Capital Market on September 3, 2025. The actual number of shares of our common stock issued will vary depending on the sales prices of the shares sold through this offering. Plan of Distribution: “At the market offering” that may be made on the Nasdaq Capital Market, or such other national securities exchange on which our common stock is then listed, from time to time through or to the Agent, as sales agent or principal. See the section titled “Plan of Distribution” of this prospectus supplement. Use of proceeds: We currently intend to use the net proceeds, if any, from this offering for clinical trials, our commercial pilot programs and for general corporate purposes including working capital. See the section titled “Use of Proceeds” of this prospectus supplement. Risk factors: Any investment in the common stock offered hereby is speculative and involves a high degree of risk. You should read the “Risk Factors” section of this prospectus supplement and the accompanying base prospectus and the documents incorporated by reference into this prospectus supplement and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as such risk factors may be amended, updated or modified periodically in our quarterly reports filed on Form 10-Q with the SEC, and any amendment or update thereto reflected in subsequent filings for a discussion of factors to consider carefully before deciding to invest in shares of our common stock. The Nasdaq Capital Market symbol: “SXTP” The number of shares of our common stock to be outstanding after this offering is based on 4,104,469 shares of our common stock outstanding as of September 3, 2025, and excludes:

| ● | 57,068                                                                                    
 shares of common stock reserved for future issuance under the 2022 Equity Incentive Plan; |

| ● | 7,587,594                                                                                   
 shares of common stock issuable upon exercise of outstanding warrants at a weighted average 
 exercise price of $5.82 per share;                                                          |

| ● | 28,437                                                                                     
 shares of common stock issuable upon exercise of outstanding options at a weighted average 
 exercise price of $23.64 per share; and                                                    |